Oct 27, 2026
RESET will assess safety, drug exposure, and biological markers over 12 weeks
Written by Andrea Lobo | Oct. 12, 2026
- Parkinson’s disease is characterized by the loss of dopamine-producing nerve cells, which contributes to movement difficulties and cognitive changes.
- The RESET Phase 2a trial is evaluating Jotrol, an oral resveratrol formulation with the potential to address pathways linked to Parkinson’s, including oxidative stress and mitochondrial dysfunction.
- Participants receive daily Jotrol or placebo to assess safety and pharmacokinetics and explore how the treatment may affect Parkinson’s symptoms.
The first patient has been dosed in a Phase 2a clinical trial evaluating Jotrol, an investigational oral formulation of resveratrol that Jupiter Neurosciences is developing for Parkinson’s disease. The trial is expected to be completed in the first half of 2029.
The RESET trial (NCT07592767) is enrolling up to 30 adults with Parkinson’s, ages 55 to 85, who are stable on standard treatments such as levodopa or dopamine agonists. The multicenter study is planned to involve about three sites in the U.S.
Oral therapy targets pathways linked to Parkinson’s
“Dosing the first patient in RESET is a significant milestone for Jupiter and the culmination of years of scientific, regulatory and clinical development work,” Christer Rosén, Jupiter’s CEO, said in a company press release. Rosén added, “With patient dosing now underway, we look forward to advancing enrollment and generating clinical data that will help us evaluate Jotrol’s potential in this significant area of unmet medical need.”
Parkinson’s disease is marked by the progressive loss of nerve cells that produce dopamine, a brain chemical that nerve cells use to communicate. The resulting loss of dopamine signaling leads to the disease’s symptoms, including movement difficulties and cognitive changes.
Several processes are thought to contribute to nerve cell damage in Parkinson’s, including brain inflammation; oxidative stress, or damage caused by harmful molecules; and problems with mitochondria, the structures that produce energy for cells.
Jotrol is a micellar formulation of resveratrol, a natural compound found in plants such as grapes, that is delivered in an oral softgel capsule. It is designed to improve resveratrol’s bioavailability — how much of the compound reaches the body and can be used — and deliver a therapeutic dose without the digestive side effects associated with other resveratrol formulations.
Jotrol can also cross the blood-brain barrier and reach the central nervous system (CNS), which includes the brain and spinal cord.
“We believe that Jotrol has the potential to address biological pathways implicated in Parkinson’s disease, including mitochondrial dysfunction, oxidative stress and neuroinflammation,” Rosén said.
Oct 26, 2026
Study found new events in 22% of patients, often eased by dose changes
Written by Marisa Horak, MS | Oct. 13, 2026
- Patients starting the advanced Parkinson’s disease treatment Vyalev may experience new psychiatric issues, particularly hallucinations or psychosis.
- New-onset psychiatric symptoms were more common in patients with pre-existing cognitive impairment.
- These psychiatric problems were generally manageable through individualized infusion-rate adjustments or low-dose antipsychotic medications.
A real-world study found that psychiatric issues, including hallucinations and delusions, developed in some people with advanced Parkinson’s disease after they started Vyalev (foscarbidopa and foslevodopa), but most were manageable with infusion-rate adjustments or low-dose antipsychotic medications.
The study, “Real-world neuropsychiatric safety profile of foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease,” was published in the Journal of Neurology.
“Our findings indicate that [Vyalev] is generally well-tolerated in routine clinical practice, with most [neuropsychiatric adverse events] being mild, transient, and manageable through individualized dose adjustments and targeted pharmacological interventions,” the researchers wrote.
How Vyalev delivers Parkinson’s treatment
Parkinson’s is a neurological disorder in which brain cells that make dopamine, a chemical messenger involved in movement, become damaged and die. Levodopa is a mainstay Parkinson’s treatment that the brain converts into dopamine. It is usually given with carbidopa, which allows more levodopa to reach the brain.
Levodopa/carbidopa therapies are usually taken by mouth. Vyalev, however, is given continuously under the skin through a specialized pump. Vyalev is approved in the U.S. and many other countries to treat motor fluctuations in adults with advanced Parkinson’s disease.
Vyalev was approved based on data from clinical trials, which found that the therapy was generally well tolerated and outperformed immediate-release oral carbidopa/levodopa at controlling symptoms of Parkinson’s disease. However, clinical trials use strict eligibility criteria, so their results may not fully reflect the wider range of patients treated in routine practice.
Researchers in Italy looked back at clinical data from 77 people with advanced Parkinson’s who started Vyalev at two specialized referral centers. When they started Vyalev, their average age was 66, and they had been living with Parkinson’s for about 14 years.
Before starting Vyalev, about half of the patients met criteria for cognitive impairment. About one in four (26%) had a history of hallucinations or psychosis, and 27% had a history of impulse control disorders. Eight patients (10%) had active neuropsychiatric problems when they started Vyalev. Hallucinations involve seeing or hearing things that aren’t there, while psychosis can include delusions, or fixed beliefs without a basis in reality. These psychiatric issues are common nonmotor symptoms of advanced Parkinson’s and can be influenced by dopamine-related treatments.
All patients who remained on treatment were followed for at least six months after initiation of Vyalev. At follow-up, assessments indicated that motor symptoms had improved, consistent with benefits seen in clinical trials.
Oct 23, 2026
Study testing Mission Therapeutics' therapy recruiting in several locations
Written by Andrea Lobo | Oct. 19, 2026
- The first patient was dosed in a Phase 1b clinical trial testing MTX325, an oral treatment for Parkinson’s.
- The trial is still recruiting participants at several locations.
- MTX325 aims to be a disease-modifying therapy by improving mitochondrial quality control through the blocking of the USP30 enzyme.
The first patient has been dosed in Mission Therapeutics’ Phase 1b clinical trial of MTX325, an oral treatment for Parkinson’s disease.
With several locations open in the U.K., France, Germany, and Australia, the Phase 1b clinical trial (NCT07630545) is still recruiting up to 36 adults aged 40-75 with mild to moderate idiopathic (of unknown cause) Parkinson’s.
The first patient was dosed at the Royal Liverpool University Hospital in the U.K. Initial data are expected in 2027.
The start of this part of the trial follows the successful completion of an earlier part conducted in healthy volunteers, which showed that the treatment was generally safe and could reach functional brain tissue.
“Dosing the first Parkinson’s disease patient is a significant milestone in the development of MTX325, a potential disease-modifying treatment for this serious neurodegenerative disease,” Sarah Fritchley, PhD, Mission’s chief development officer, said in a company press release.
Oct 22, 2026
Research funding, chemical bans among suggestions from experts
Written by Marisa Horak, MS | Oct. 16, 2026
- Experts outlined an eight-step strategy focused on primary prevention to eliminate Parkinson’s disease and address rising incidence rates.
- Key risk factors include genetic variations and environmental exposures to toxic chemicals like paraquat and trichloroethylene.
- Primary prevention efforts require policy changes to ban harmful chemicals and $600 million in annual NIH research funding.
In late 2025, the Parkinson’s Foundation and the Fixel Institute at the University of Florida brought together dozens of experts to ask a bold question: What will it take to bring about a world where no one has Parkinson’s disease?
Now, that group — the Parkinson’s Disease Prevention Think Tank — has put out a paper outlining the key steps that will need to be taken. The paper, “Primary prevention of Parkinson’s disease: proceedings, the 8C’s and a position statement from the Parkinson’s disease prevention think tank,” was published in npj Parkinson’s disease.
The group identified what it called “eight Cs,” priority actions needed to eliminate the disease: Count incidence and prevalence, conduct studies, create policy change — this includes urging the U.S. Environmental Protection Agency to ban toxic chemicals linked to Parkinsons’ — counsel on risk, communicate clearly, form coalitions across disease organizations, apply cross-disciplinary approaches involving health economists and toxicologists, and financial commitment in the form of $600 million in research funding from the National Institutes of Health.
“Our goal is to draw attention to primary prevention by advancing research and shaping policy,” Sneha Mantri, MD, chief medical officer of the Parkinson’s Foundation and the paper’s lead author, said in a foundation press release. “ Our report outlines the actions needed on the individual and system level to make this vision a reality.”
Oct 21, 2026
4-week program on food-med interaction boosts physical, mental quality of life
Written by Michela Luciano, PhD | Oct. 15, 2026
- Dietary proteins compete with Parkinson's medication for intestinal absorption and brain transport.
- A four-week nutrition education program focusing on food-drug interactions significantly improved patients' physical and mental quality of life.
- Patients learned to optimize treatment efficacy by timing protein-rich meals away from levodopa doses and shifting protein intake.
A four-week nutrition education program focused on how food interacts with Parkinson’s disease medications was tied to improved physical and mental quality of life for patients, a small study in Turkey found.
The program helped participants adjust their eating habits, providing guidance on timing protein-rich meals around doses of levodopa, the main treatment for Parkinson’s disease. After the intervention, participants reported improved physical and mental well-being, along with changes in their nutrient intake.
The findings suggest that helping people with Parkinson’s understand food/medication interactions could improve their quality of life and dietary habits. However, the researchers cautioned that the study involved only 30 participants and lacked a comparison group, making it difficult to determine whether the improvements were attributable to the education program.
“To further validate and expand upon these promising findings, the long‐term efficacy of such targeted nutritional interventions should be demonstrated in future large‐scale, randomized controlled trials,” the researchers wrote.
The study, “Effects of food–drug interaction-oriented nutritional education on quality of life in Parkinson’s disease: A pilot quasi-experimental study,” was published in Nutrition in Clinical Practice.
Recent Comments